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Wound healing involves inflammation, cell prolifera- epithelialization of the wounds. An increase in the
synthesis of collagen, fibronectin and transformingtion, matrix deposition, and tissue remodeling.
growth factor-b1 was seen in arnebin-1-treated woundsInteraction of different cells, extracellular matrix pro-
compared with the untreated control. As transformingteins, and their receptors are mediated by cytokines
growth factor-b1 is known to enhance wound healing,and growth factors during wound healing. In this
and associated with the wound healing defect in hydro-study, we have evaluated the effect of arnebin-1, a
cortisone-treated wounds, the enhanced expression ofnatural product isolated from Arnebia nobilis, on normal
transforming growth factor-b1 at both translationaland impaired wound healing in cutaneous punch
and transcriptional level by arnebin-1 may be respons-wound model. Arnebin-1 was applied topically daily ible for the enhancement of wound healing during
on wounds of hydrocortisone-treated or untreated normal and impaired wound repair. These studies
animals. Arnebin-1 significantly accelerated healing of suggest that arnebin-1 could be developed as a potent
wounds with or without hydrocortisone treatment as therapeutic agent for wound healing in steroid-
revealed by a reduction in the wound width and gap impaired wounds. Key words: extracellular matrix
length compared with controls. Arnebin-1 treatment proteins/impaired wound repair/punch wound model/
promoted the cell proliferation, migration, and vessel transforming growth factor-b1. J Invest Dermatol 113:773–
781, 1999formation to form a thick granulation tissue and re-
W cell types in the wound bed (Mustoe et al, 1987; Mooney et al,1989; Falang, 1993; Brown et al, 1994). The use of recombinantgrowth factors alone or in combination has been shown to enhancethe tissue repair and regeneration in animals and humans (Rotheand Flanga, 1989; Mustoe et al, 1991). These growth factors are
mainly released from the various cells in the wound bed especially
ound healing is a complicated biologic process
which involves interactions of multiple cell
types various cytokines, growth factors, their
mediators, and the extracellular matrix proteins
(ECM). Fibronectin (FN), laminin (LMN),
tenascin, and collagen are extracellular matrix proteins not only
macrophages, and trigger other cells to migrate, proliferate, orinvolved in the early phase of the wound healing but also play an
produce other growth factors required for repair (Rappolee et al,important part in structural remodeling of the tissue. ECM inter-
1988; Mckenzie and Sauder, 1990). Granulocyte macrophage-action supports the adhesion of fibroblasts and endothelial cells
colony stimulating factor and vascular endothelial growth factor(Fujikawa et al, 1981; Hunt, 1988; Mackie et al, 1988; McDonald,
enhance wound healing in ischemic tissue by inducing vasculogen-1989; Martin et al, 1992). Several cytokines/growth factors such as
esis and neovascularization (Kalka et al, 1999). Thus induction oftransforming growth factor (TGF)-β and -α, platelet-derived
growth factors in the wound by any agent would provide bettergrowth factor, epidermal growth factor (EGF), basic fibroblast
perspectives for the consideration as a potent wound healing agent.growth factor, and insulin-like growth factor-1 (IGF-1) play a
Arnebia nobilis is one of the four species of the genuscentral part in wound healing by regulating recruitment, activation,
(Boraginaceae) occurring in northern India. The extract of A. nobilismitogenesis, migration, angiogenesis, and differentiation of various
was widely used for centuries in indigenous medicine for wound
healing treatment. Investigations on the extract from the root of
this plant led to isolation of four naphthaquinones designated as
Manuscript received January 21, 1999; revised July 1, 1999; accepted arnebin-1, arnebin-2, arnebin-3, and arnebin-4, which have been
for publication August 5, 1999 characterized by the Central Drug Research Institute (CDRI),
Reprint requests to: Dr. Radha K. Maheshwari, Department of Lucknow (India). Arnebin-1 was most active against Walker carcin-
Pathology, Uniformed Services University of the Health Sciences, 4301 oma in rats and P388 lymphoid leukemia in mice (Shukla et al,
Jones Bridge Road, Bethesda, MD-20814. Email: rmaheshwari@usuhs.mil 1969) in contrary to arnebin-2 which do not have any anti-tumorAbbreviations: HDMEC, human dermal microvascular endothelial
activity. Arnebin-1 (5,8-dihydroxy-2-(19-b,b-dimethylaryoxy-49-cells; HDF, human dermal fibroblasts; HM, human melanocytes; ICE,
methylpent-3-enyl)-1, 4-naphthoquinone exhibited a wide rangeinterleukin-1β converting enzyme; PBMC, peripheral blood mono-
of biologic activities such as anti-cancer, anti-bacterial, anti-fungal,nuclear cells.
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sections from each test were incubated with normal serum IgG separately.This study was undertaken to evaluate the in vivo effect of
Slides were washed with PBS. Biotinylated secondary antibody IgG(H 1 L)arnebin-1 on wound healing. We observed a faster closure of
was added for 1 h, followed by avidin–biotin–peroxidase complex forunimpaired and hydrocortisone-impaired wounds in a full thickness
30 min. Slides were then stained with diaminobenzidine, and counterstainedpunch wound model in rats as revealed by a decrease in the wound
with Harris hematoxylin, and eosin.gap and wound width in arnebin-1 treated rats compared with Immunostaining for α-actin was performed in mice to identify myofib-
controls. Arnebin-1 promoted the wound healing by inducing the roblasts in the granulation tissue, using anti-smooth muscle α-actin antibody,
proliferation of cells, angiogenesis, and collagen synthesis. FN and immunoglobulin G (IgG2a murine monoclonal, Boehringer Mannheim
TGF-β1 were also transcriptionally upregulated in wounds by Biochemicals, Indianapolis, IN) by an indirect avidin–biotin–immunop-
eroxidase technique as described above.arnebin-1. The increased biosynthesis of FN, collagen and TGF-
β1 by arnebin-1 may be responsible for the enhancement of
Laser scan cytometry for TGF-b1 The Laser Scan Cytometer (LSC)wound healing.
measures multiple fluorescence and light scatter. Once the area of the tissue
MATERIALS AND METHODS is gated, LSC automatically identifies cells, measures fluorescence and can
differentiate between nuclear and cytoplasm fluorescence. In order toAnimals Male Sprague–Dawley strain rats 250–300 g were purchased compare the relative density of intracellular immunostaining for TGF-β1from Charles River laboratory. The animals were used in compliance with in the control and treated wounds, we performed laser scan cytometry bythe US Public Health Service policy on humane care and use of animals. using LSC (CompuCyte, Cambridge, MA). Briefly, slides were deparaf-The animals were housed in a room with 12 h light/12 h dark cycle and finized in xylene, hydrated, and permeabilized with 0.025% saponin forwere fed Purina FOX chow and water ad libitum. 15 min, and then washed with PBS containing 0.5% bovine serum albumin.
Sections were incubated with fluorescein isothiocyanate (FITC)-conjugatedTreatment Rats were randomly selected and divided into four groups: anti-TGF-β (Santa Cruz Biotechnologies, CA) for 30 min. Followed byvehicle control, hydrocortisone, arnebin-1, and hydrocortisone plus arne- several washings, sections were counterstained with propidium iodidebin-1. Arnebin-1 [0.1% aqueous suspension in phosphate-buffered saline (PI, 2 µg per ml) to stain the nuclei containing 1 unit of RNAse for(PBS)] was applied on the day of wounding and onwards daily for 30 min in the dark. Slides were mounted with 50% glycerol in PBS and11 d whereas the vehicle control animals received PBS on the wounds. the fluorescence signal was quantitated by LSC using CompuCyte protocol.Hydrocortisone (30 mg per kg i.m.) was given daily throughout the 11 d The FITC counts were graphically represented to compare the FITCperiod. Each experiment including all the groups was done three times. integral in the different groups.
Creation of wound The animals were anesthetized using pentothal
Proliferating cell nuclear antigen (PCNA) staining in the(35 mg per kg, i.p.) and hair on the dorsal side of subjects were shaved
wound PCNA is a 37 kDa molecular weight protein and is seen to beand the skin was cleaned with 70% ethanol. An 8 mm skin biopsy punch
strongly associated in the nuclear region where DNA synthesis is occurring.(Acuderm, Ft Lauderdale, FL) was used to create full thickness dorsal
The cells actively synthesizing DNA are detected by PCNA staining.cutaneous wound under aseptic condition as described previously (Sidhu
Immunostaining was performed using monoclonal anti-PCNA antibodyet al, 1998; Bharatiya et al, 1992). Six wounds with three on each side in
(Calbiochem, MA) by an indirect avidin–biotin–immunoperoxidase tech-each rat were created, and thereafter, the animals were individually caged.
nique (Vectastain ABC Elite) as described above for TGF-β1 staining. The
cells in the granulation tissue was evaluated for PCNA staining by averagingHistopathologic studies Six rats from each group were killed on the
the number of cells in 10 high power fields (100 3 objective), midway infourth, seventh, and eleventh days after wounding using pentothal
the wound bed.(35 mg/kg, i.p.) anesthesia. Wound tissues were excised and cut into
halves; one half was collected in formalin (10% formaldehyde in PBS) for
Polymerase chain reaction (PCR) analysis of mRNA transcripts ofhistology, hematoxylin and eosin staining, and in situ hybridization; the
FN and TGF-b1 On the fourth day postwounding, the animals weresecond half was quickly washed in cold sterile diethylcarbonate (DEPC)-
killed, wounds were excised, washed in PBS containing DEPC, and totaltreated PBS for RNA preparation. Serial sections (5–6 µm thick) were
RNA was extracted immediately from tissues with the use of RNAzol Bstained with hematoxylin and eosin for histologic evaluation and morpho-
kit (Tel-Test, Friendwood, TX) as specified by the manufacturer. Themetry. Masson’s Trichrome method for staining collagen was performed
RNA was further purified by lithium chloride precipitation, and analyzedon paraffin sections followed by photomicrography.
by electrophoresis in a denaturing 1.5% formaldehyde gel to ascertain that
the RNA was not degraded. RNA was reverse transcribed as describedMorphometric measurements and analysis An ocular micrometer
previously (Sidhu et al, 1998). The cDNA was amplified by PCR usingwas calibrated with the stage micrometer. Morphometric readings were
sense and anti-sense specific primer. Briefly, to 3 µl of the reversenoted using the ocular micrometer and then converted to actual measure-
transcriptase mix, the following components were added; 10 µl of 10 3ments in micrometers (µm). All morphometric measurements were done
PCR buffer and 0.5 µl of Taq polymerase (5 µl); 6 µl of dNTP; 0.4 µl offrom sections through the center of the wounds so as to obtain maximum
sense primer (1 µg per µl) and 0.4 µl of anti-sense primer (1 µg per µl)wound diameter. The measurements were performed three times, by
and 79.7 µl of water. The samples were incubated in a DNA thermocyclerstudying the slides in different random sequence, blinded to treatment.
(Gene Amp PCR system 9600, Perkin Elmer Cetus, Norwalk, CT) forEpidermal migration was measured from the left and right margins of the
25 cycles. To confirm that equal amounts of RNA were taken in eachwound, and the readings were added to ascertain total migration. In
PCR reaction in the experiment, primers for the ‘‘house keeping gene’’,addition, the thickness of the newly formed epidermis was measured at
glyceraldehyde phosphate dehydrogenase (GAPDH) were used for compar-1 mm intervals, and the mean calculated. The density of granulation tissue
ison. The primers used for DNA amplification were specific for TGF-β1,was evaluated by averaging the number of cells in six high power fields
FN, and GAPDH to the rat sequence. The location of primers for(60 3 objective), midway in the wound bed. We also counted the number
nucleotide sequence amplification of amplified DNA product on southernof vascular spaces in six high power fields (60 3 objective), midway in
blot were bases: 1271–1292 (sense), 1510–1491 (anti-sense), and 1401–the wound bed. Dermal thickness was determined at the center of each
1421 (probe) for TGF-β1; 1657–1677 (sense) and 2070–2050 (anti-sense),section, vertically, from the surface of granulation tissue to the margin of
and probe (1830–1850) for FN; 388–405 (sense), 581–562 (anti-sense),dermis and subcutis. Eschar, where present, was not included in this
and 531–549 (probe) for GAPDH. The sequences for anti-sense probesmeasurement. Readings obtained in treated and control groups were
were selected from cDNA for TGF-β1, FN, and GAPDH, were examinedcompared and statistical analysis carried out using paired Student’s t test.
for sequence homology in the GENE BANK, and were found to be
gene specific.Immunohistochemical staining for TGF-b and a-actin
The final PCR products from each sample were run on 1% GTGImmunostaining was performed using rabbit polyclonal TGF-β1 antibody
agarose (Seakem, Rockford, ME), blotted to nytran membrane (Schleicher(Santa Cruz Biotechnology, CA) by an indirect avidin–biotin–immuno-
and Schuell, Keene, NH) and hybridized to 32P (NEN, Boston, MA),peroxidase technique (Vectastain ABC Elite, Vector laboratories, Burlin-
end-labeled oligoprobes at 42°C for 8 h and autoradiographed.game, CA) as specified by the manufacturer. Briefly, sections were placed
on poly L-lysine-coated slides, deparaffinized, and hydrated. Endogenous
peroxidase activity was blocked with hydrogen peroxide in methanol for In situ hybridization This was performed as described (Diamond et al,
1990) with slight modifications. Briefly, the slides were fixed in 4%10 min. Non-specific staining was blocked with normal serum, and the
sections were incubated with monoclonal anti-human TGF-β antibody for paraformaldehyde and acetylated for 10 min, dehydrated, and hybridized
for 18 h at 42°C. Plasmid PBR322 containing murine cDNA was a10–16 h at 4°C. To ascertain that the reaction of antibody was specific,
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Figure 1. Arnebin-1 enhanced wound healing in rats. Vehicle control and arnebin-1-treated hematoxylin/eosin-stained sections of fourth and
seventh day punch wounds. A loose crust over the epithelial loss was seen in both control and arnebin-1-treated wounds at 4 d postwounding. Middle
panel is the magnified dermis near dermal and epidermal junction. An increase in the number of cells and blood vessels are seen in the dermis. Higher
magnification of dermal area, showing an increase in the number of cells and blood vessels in arnebin-1-treated wounds compared with controls. Seven
day control wounds showing migrating epithelium over the dermis. Arnebin-1 treatment resulted in complete re-epithelialization of the wounds by the
seventh day. Masson’s trichrome (MT) staining shows collagen in blue. Arnebin-1 treatment enhanced collagen production on both the fourth and
seventh days postwounding. Scale bar: (top panels) 50 µm; (middle panels) 5 µm; (bottom panels) 10 µm. e, epidermis; d, dermis; me, migrating tongue of
the epithelium. Arrows show the blood vessels.
generous gift from Dr Helen Coon, USUHS, Bethesda, MD. Murine ill-formed granulation tissue with a few newly formed capillary chan-
cDNA insert was excised, and purified murine cDNA insert of TGF-β nels, and sparse collagen. Arnebin-1-treated wounds show more
was labeled with [α-35S] dCTP (ICN Biomedical, Irvine, CA) (1000 Ci number of cells and vessels in the granulation tissue. On the seventh
per mmol) with random primers. Hybridization was performed using daypostwounding, vehicle-treatedcontrolwounds showedepithelial
solution containing 0.1 mg 35S-labeled cDNA probe per ml, 10 mM migration over the dermis whereas the arnebin-1-treated wounds
dithiothreitol, 500 mg acetylated bovine serum albumin per ml, 0.3 M showed a well-formed and differentiated epidermis. Organization ofsodium chloride, 50% deionized formamide, 10% (wt/vol) dextran sulfate,
the granulation tissue was also more advanced with thick bundles of500 mg per ml tRNA, 0.02% polyvinylpyrrolidone, 0.02% Ficoll, 1 mM
well-aligned collagen in arnebin-1-treated wounds.ethylenediamine tetraacetic acid, and 50 mM Tris/HCl, pH 7.6. Posthybrid-
The epidermal regeneration was enhanced by arnebin-1 in hydro-ization was performed by sequential incubation of the slides in a progressively
cortisone-treated wounds on the fourth and eleventh days post-more dilute salinecitrate solution with 5 mM dithiothreitol and 0.1%
Triton-X, dehydrated, and dipped in NTB3 emulsion for autoradiography. wounding (Fig 2). On the fourth day postwounding, arnebin-1
After exposure for 7–10 d at 4°C, the slides were developed with D19 treatment in hydrocortisone-treated rats in resulted the formation of
developer, stained with eosin and mounted with permount. The cells were dense granulation tissue with arborizing capillary channels, whereas
examined and photographed with a Zeiss microscope equipped with inflammatory cells and a few vessels were seen in the granulation
camera attachments. tissue of controls. Arnebin-1 treatment induced the collagen synthesis
Masson’s Trichrome and immunohistochemical staining, and in situ in hydrocortisone-treated wounds. Wounds on the eleventh day
hybridization were performed on eight to 10 wounds with 10–12 serial were much healthier in arnebin-1-treated groups. Organization ofsections of each wound to assess the reproducibility of the wounds. the granulation tissue was also more advanced in arnebin-1-treated
wounds with thick bundles of well-aligned collagen compared withRESULTS
controls.
Morphologic changes in arnebin-1 treated and the control Morphometric analysis of the histologic sections of the wounds
wounds Multiple cross-sections of hematoxylin and eosin stained confirmed that arnebin-1 enhanced the formation and migration of
sections of arnebin-1 treated and untreated biopsy punch tissues of the epidermis over the wound (Table I). Quantitation of epidermal
rats were examined for epithelial regeneration, infiltration of cells, migration in arnebin-1-treated wounds showed a statistically signi-
density of newly formed vessels, and the organization of the granula- ficant increase in migration of epidermal tongues as compared with
tion tissue. Wound organization was assessed in terms of degree of controls. Arnebin-1 treatment resulted in the formation of thick
collagenization and alignment of collagen fibers parallel to the skin epidermis in normal wounds compared with controls and hydrocor-
surface. Arnebin-1 treatment enhanced wound healing in both unim- tisone-treated wounds. There was no apparent difference in the
paired and hydrocortisone-impaired wounds (Figs 1 and 2). On the thickness of migrating epidermis between either of hydrocortisone
fourth day postwounding (Fig 1), there was no or minimal epidermal alone or hydrocortisone and arnebin-1-treated wounds (Table I),
suggesting that steroids did not affect the thickness of the epidermis.migration in the control wounds and the underlying dermis showed
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Figure 2. Arnebin-1 enhanced wound healing in hydrocortisone (HC)-treated rats. Hematoxylin/eosin-stained sections of fourth and eleventh
day punch wounds. A loose crust over the epithelial loss was seen in control and arnebin-1-treated wounds at 4 d postwounding. Migrating epithelium
is seen in arnebin-1-treated wounds. Middle panel is the magnified dermis near dermal and epidermal junction. Inflammatory cells and neovascularization
is seen at fourth day control wounds in the dermis, whereas the dermal area is infiltrated with a large number of cells and vessels in arnebin-1-treated
wounds. Eleven day hydrocortisone-treated wounds shows epithelial regeneration over the dermis, and immature granulation tissue infiltrated with a
large number of cells and mild neovascularization. Arnebin-1 treatment in hydrocortisone-treated wounds, showing migrated epithelium, and matured
granulation tissue with the disappearance of the microvessels. Masson’s trichrome (MT) staining shows collagen in blue. Arnebin-1 treatment enhanced
collagen production compared with control wounds Collagen was loosely arranged in the control whereas well aligned collagen fibres are seen in arnebin-
1-treated wounds. Scale bar: (top panels) 50 µm; (middle panels) 5 µm; (bottom panels) 10 µm. Arrows shows the vessels. e, epidermis; d, dermis; me, migrating
tongue of the epithelium. Arrows show the blood vessels.
Table I. Epithelial migration from the wound edge and
thickness of the epithelial layer on the seventh day
postwoundinga
Treatment Epithelial migration Thickness of the epidermis
(µm) (µm)
Vehicle control 2423 6 121 120 6 24
Arnebin-1 4508 6 267b,d 288 6 46a
HC 1467 6 115b 138 6 19
HC 1 arnebin-1 3532 6 327b,c 151 6 29
aEpithelial migration from both the edges of the wound was measured with ocular
micrometer using microscope. Each measurement is average of 36 wounds and the Figure 3. Arnebin-1 increased gap closure during normal and
values are expressed as mean of epithelial migration 6 SEM or thickness of the impaired healing. Arnebin-1 treatment increased gap closure (re-epithelium 6 SEM.
epithelialization) in both control and hydrocortisone-treated wounds onbp , 0.001; significant difference from vehicle control.
the fourth day postwounding. This trend continues and on the seventhcp , 0.001; significant difference from hydrocortisone treated controls) (Student’s
day, the arnebin-1-treated wounds were almost completely closed in normalt test).
dNinety per cent of animals treated with arnebin-1 showed complete re- healing, whereas the wounds were not completely closed in impaired
epithelialization of the wound. HC, hydrocortisone. healing; however, the gap closure was significantly increased in arnebin-
1-treated wounds compared with hydrocortisone-treated controls.
Measurements are expressed as the mean of gap length 6 SEM, n 5 18.
Re-epithelialization and contraction of treated wounds (*p , 0.001, significant difference from vehicle control, **p , 0.001,
Wounds treated with arnebin-1 showed a statistically significant significant difference from hydrocortisone-treated control, 11p , 0.0001,
decrease in the epidermal gap between the migrating tongues of significant difference from normal and hydrocortisone-treated control,
epidermis as compared with vehicle control and hydrocortisone- Student’s t test). C, control; ARN, arnebin-1; HC, hydrocortisone.
treated wounds (Fig 3). This increase in the re-epithelialization was
also observed in wounds treated for 7 d and the rate of gap closure
was slightly accelerated over that observed at day 4. The rate of re- 7 d. After 4 d of arnebin-1 treatment, wounds showed a statistically
significant difference in the decrease of wound width in both normalepithelialization in hydrocortisone-treated wounds, however, was
slower as compared with control wounds. and hydrocortisone-treated wounds as compared with controls
(Fig 4). The decrease in the wound width was also observed at dayContraction (width) of the wounds was also evaluated at both 4 and
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Figure 4. Arnebin-1 reduced wound width in normal and impaired
wounds. Arnebin-1 treatment decreased the wound width (contraction
of dermis) of normal and hydrocortisone-treated wounds on both the
fourth and seventh day postwounding. Measurements are expressed as the
mean of wound width 6 SEM, n 5 12. (*p , 0.001, significant
difference from vehicle control, **p , 0.001, significant difference from Figure 6. Arnebin-1 increased proliferating cells in the granulation
the hydrocortisone-treated control, Student’s t test). C, control; tissue at the fourth day postwounding. PCNA staining was performed
ARN, arnebin-1; HC, hydrocortisone. in paraffin-embedded sections of the wounds and the PCNA positive cells
were counted in the entire section of the wound. The mean numbers cells
per 12 high power fields (1003) was calculated for each wound and
averaged for the group (i.e., control or treated). Arnebin-1 treatment
significantly increased the number of proliferating cells in the granulation
tissue of both normal and impaired wounds. Values are expressed as the
mean number of PCNA positive cells 6 SEM. Student’s t test was applied
for statistical analysis. *p , 0.0001, significant difference from control
wounds, and **p , 0.001, difference from hydrocortisone-treated controls.
C, control; ARN, arnebin-1; HC, hydrocortisone.
indicating arnebin-1 treatment resulted in considerable capillary
ingrowth.
The migration and the proliferating of cells into the wound bed
promote wound healing by secreting various growth factors and
extracellular matrix proteins. PCNA staining showed an increase in
the proliferating cells in the granulation tissue in arnebin-1-treated
wounds compared with controls during normal and impaired healing
(Fig 6), suggesting that arnebin-1 facilitated the infiltration of prolif-
erating cells into the wound bed. Arnebin-1-treated wounds consist-
ently showed a greater influx of cells. To determine whether the
infiltrating cell population contains myofibroblasts, sections were
stained with SM α-actin. Many of the proliferating cells in the control
and arnebin-1-treated wounds were positive for SM α-actin staining,
indicating the presence of myofibroblasts in the granulation tissue of
Figure 5. Density of vessels in the granulation tissue on the fourth the wounds (Fig 7). Arnebin-1-treated wounds showed an increaseday postwounding. Vascular spaces as identified by endothelial-lined
in the number of myofibroblasts compared with controls. Thechannels were counted in the entire cross-section of the wound bed. The
increase in the number of myofibroblasts, and the accumulation/mean numbers of blood vessels per 10 high power fields (403) were
biosynthesis of collagen in arnebin-1-treated wounds supports thecalculated for each wound and averaged for the group (i.e., control or
observation of decreased wound width, suggesting a role for arnebin-treated). Vessel counts are significantly higher in arnebin-1-treated wounds
on the fourth day postwounding as compared with controls showing a 1 in wound contraction.
richer granulation tissue formation after arnebin-1 treatment. Values are
Effect of arnebin-1 on TGF-b1 induction TGF-β1 was local-expressed as mean number of vessels 6 SEM. Student’s t test was applied
ized in arnebin-1-treated and untreated wounds. The brown colorfor statistical analysis. (*p , 0.001, n 5 12 significant difference from
control, and ap , 0.001, n 5 12 significant difference from hydrocortisone- indicates the staining for TGF-β1. A large number of cells especially
treated control). C, control; ARN, arnebin-1; HC, hydrocortisone. the fibroblasts show staining for TGF-β1 in arnebin-1-treated
wounds compared with controls (Fig 8). On the seventh day post-
wounding, the epidermis of the arnebin-1-treated wounds showed7. These data demonstrate that arnebin-1 treatment increases wound
staining for TGF-β1, whereas no staining was observed in the epi-re-epithelialization and contraction, suggesting that arnebin-1
dermis of the controls (Fig 8).enhanced wound closure in both normal and healing-impaired
This was further brought out by FITC integral analysis on laseranimals.
scan cytometry following immunofluorescence staining (Fig 9). The
same site of the control and arnebin-1 treated wound was gated forArnebin-1 treatment enhanced the formation of granulation
tissue Granulation tissue is composed of new blood vessels, colla- the quantitation of the expression of TGF-β1 using LSC. The left
panel of Fig 8 shows the intensity of the PI indicating the number ofgen, and several cell types including fibroblasts, myofibroblasts, and
macrophages. We investigated whether the healing wounds showed cells in the control and arnebin-1-treated wounds. The right-hand
panel (Fig 9) shows the amount of fluorescence obtained from FITCany increases in the angiogenesis by counting the blood vessels in the
dermis. Vessel counts showed a significant increase (4-fold) in the and represents the population of cells positive for TGF-β1. As evident
from Fig 9, arnebin-1 treatment increased the expression of TGF-number of vessels in arnebin-1-treated wounds on the fourth day
postwounding in both normal and impaired healing animals (Fig 5), β1 along with the cell population in granulation tissue.
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Figure 7. SM a-actin staining in
fourth day rat wounds. Immuno-
staining was performed using anti-α-
smooth muscle (SM)-actin antibody,
immunoglobulin G (IgG2a murine
monoclonal) by an indirect avidin–biotin–
immunoperoxidase to look for myo-
fibroblasts. Arnebin-1 treated wound,
showing a larger number of positive staining
cells compared with control. Scale
bar: 2.5 µm.
Figure 8. Immunohistochemical stain-
ing for TGF-b1 in wounds. Immuno-
staining was performed using rabbit
polyclonal antibody to TGF-β1 (SantaCruz
Biotech, CA), and avidin–biotin–immuno-
peroxidase, Vectastain ABC Elite kit. Fourth
day (top panel)and seventh day (bottom panel)
post-wounding. Arnebin-1-treated wounds
show more numbers of positively stained
cells as well as a greater intensity of staining at
both fourth and seventh day postwounding.
Arnebin-1-treated wounds show an
increased staining for TGFβ1 in the
epidermis compared with that of control
wounds. d, dermis; e, epidermis. Scale
bar: (top panels) 50 µm; (bottom panels) 5 µm
for each 4 and 7 day wounds. Arrows indicate
the cell showing TGFβ1 expression.
Arnebin-1 increases mRNA transcripts of FN and TGF- that arnebin-1 enhanced the expression of both TGF-β1 and FN in
the wounds.b1 Growth factors and ECM proteins play important parts in many
phases of wound healing; therefore, we selected TGF-β1 from In an another experiment, we localized the mRNA expression
of TGF-β1 by in situ hybridization on paraffin-embedded tissuegrowth factors and FN from ECM. To determine whether arnebin-
1 treatment was enhancing the biosynthesis of TGF-β1 and FN, we sections from the wounded area. A few grains were observed in
the vehicle-treated wounds when the tissue was hybridized withexamined their transcripts using in situ hybridization and reverse
transcription–PCR. An increase in the mRNA transcripts of FN the cDNA of TGF-β1, indicating the basal level presence of TGF-
β1 during normal healing (Fig 11a). A large number of grains(130% 1 48%) and TGF-β1 (117% 1 32%) was observed in arnebin-
1-treated wounds compared with vehicle control (Fig10), suggesting were present in arnebin-1-treated wounds indicating an increased
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Figure 9. Quantitative analysis of
TGF-b1 expression by LSC in fourth
day wounds Paraffin-embedded sections
were processed, incubated with FITC-
conjugated-anti-TGF-β1 antibody for
TGF-β1 staining in the cytoplasm of the
cells, and counterstained with PI for nuclear
staining. Similar sites from the granulation
tissue of the control as well as arnebin-1-
treated wounds were gated for measuring
the fluorescence. Left panel shows the PI
staining representing number of cells. Right
panel shows the FITC staining for TGF-
β1 versus number of cells from the gated
area. As it is evident, the arnebin-1-treated
wounds resulted in the increase of TGF-
β1 positive cells compared with control;
however, the TGF-β1 expression was
several times more compared with the
increase in the number of cells, indicating
that arnebin-1 enhanced the expression in
the individual cells compared with controls.
in which growth factors trigger cell growth, but is an integration
of dynamic interactive processes involving cells, ECM and their
receptors, and soluble mediators (Clark, 1993). This is especially
true of healing by secondary intention as occurs in a nonincisional
wound spanning a large surface area. Thus the punch wound model
is a desirable method to evaluate the various parameters involved
in the biology of wound repair.
Glucocorticoids constitute a potent class of anti-inflammatory
compounds. The adverse effects of glucocorticoid therapy is the
inhibition of wound healing in humans and other animal models.
The mechanisms of improvement are not entirely clear but several
forms of impairment result from a decrease in the proliferation of
inflammatory cells or a delay in the inflammatory phase of wound
healing and consequently inadequate tissue formation. Formation
of healthy granulation tissue with neovascularization is a prerequisite
for healing. Also, this granulation tissue provides the medium for
epidermal cells from the wound margin to migrate and bridge the
gap. Arnebin-1 treatment resulted in an increased formation of
granulation tissue, including greater cellular content and neovascu-
larization, and a faster re-epithelialization of the wound in both
normal and impaired punch wounds as compared with their
respective control wounds, demonstrating that arnebin-1 treatment
enhanced wound healing. During granulation tissue formation,
as the contraction proceeds and resistance increases, fibroblasts
differentiate into myofibroblasts (Skalli and Gabbiani, 1988;
Rudolph et al, 1992; Petroll et al, 1993). The presence of myofibro-
blasts is considered to be the characteristic of tissue undergoingFigure 10. mRNA transcripts of FN and TGF-b1 in fourth day
contraction (Darby and Gabbiani, 1990; Desmouliere et al, 1993).wounds of rats. Reverse transcription/PCR product was blotted and
The abundance of myofibroblasts in arnebin-1-treated wounds,southern hybridization was performed using 32P oligos probe for FN or
signifies the advanced stage of healing in these wounds as comparedTGF-β1 or GAPDH. GAPDH was used as an internal control. PCR bands
were quantitated in NIH image program (Version 1.5.9) using the gel with controls.
plotting macros. The signals for TGF-β1 and FN were normalized for the The process of postinflammatory wound healing and regeneration
GAPDH and the percentage increase was calculated. The results are is characterized by a complex, multicomponent cascade of degradat-
expressed as a percentage increase 6 SEM. ive and biosynthetic reactions that direct underlying cell–cell and
cell–ECM interactions (Hunt, 1988). ECM proteins are well known
expression of TGF-β1 as compared with vehicle-treated wounds to be important in many phases of wound healing. FN helps in
(Fig 11a). Higher magnification of the dermis revealed that the the phagocytosis of wound debris and promotes the migration of
prominent cells showing hybridization were macrophages in both wound fibroblasts, endothelial cells, and epithelial cells over the
control and arnebin-1-treated wounds (Fig 11b). wound. Collagen type III is increased in the early granulation tissue
and is replaced by collagen type I (Kirsner and Eaglestein, 1993).DISCUSSION These two collagens impart strength to the healing wound. Collagen
and FN are also chemotactic for fibroblasts. Increased expressionWound healing is a highly ordered and well coordinated process
of collagen and FN by arnebin-1 suggested that arnebin-1 indirectlythat involves inflammation, granulation, fibrogenesis, neovasculariz-
helped in the remodeling and regeneration of tissues as well as theation, wound contraction, and resurfacing of the wound defect
with the epithelium. Wound healing is not a simple linear process provision of strength to the wounded tissues.
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Figure 11. In situ hybridization for
mRNA TGF-β1 in fourth day wounds.
(a) Black grains indicate mRNA
hybridization for TGF-β1. Negative
control: wound section hybridized with
plasmid vector pBR322 from which TGF-
β1 cDNA was excised. Positive control:
a wound treated with a known inducer
(curcumin) of TGF-β1. Lack of grains on
hybridization with a plasmid in the negative
control, and a large number of grains
present in the positive control indicate the
degree of specificity of the probe. Low
number of silver grains in the control
wound, and a large number of silver grains
in arnebin-1-treated wound, indicated that
arnebin-1 treatment induced the mRNA
expression of TGF-β1. Photomicrographs
were taken of the granulation tissue near
the dermal and epidermal junction. Scale
bar: 50 µm. (b) Higher magnification of
the dermal region shows that the signal
intensity is seen mainly in macrophages, and
is prominent in arnebin-1-treated wounds.
Scale bar: 10 µm. Arrows indicate the cell
showing mRNA expression for TGF-β1.
The peptide growth factors, cytokines and their receptors, which granulation tissue fibroblasts (Meisler et al, 1997). An increased
expression of interleukins-1α and -1β, and tumor necrosis factorare expressed by various cell types at the site of injury, play a key
part in regulating repair processes. This regulation is highly complex, α has been demonstrated during normal repair and this induction
was significantly lower in healing-impaired glucocorticoid-treatedinvolving the individual action of and/or synergistic interactions
among many substances. These include various members of the animals (Hubner et al, 1996). Recently, it has been shown that
systemic glucocorticoids treatment caused a severe defect in woundgrowth factor family/cytokines, such as basic fibroblast growth
factor, platelet-derived growth factor, IGF-1, TGFα, and TGF-β. repair that was accompanied by reduced expression of platelet-
derived growth factor A and B and of B type receptor in the earlyGrowth factors have improved healing in animals impaired with
diabetes, malnutrition, infection, hypoxia, hydrocortisone, and phase of wounding (Beer et al, 1997). These altered balances may
underlie healing defects associated with steroids use and may explainradiation (Greenhalgh, 1996). The role of TGF-β has been suggested
during impaired wound healing. The TGF-β belong to a superfam- beneficial effects of TGF-β1 therapy in improving wound healing
in glucocorticoid-treated animals (Slavin et al, 1992). TGF-β1 canily of proteins that regulate cellular growth, differentiation, angio-
genesis, chemotaxis, cell migration, and ECM (O’Kane and Fergu- prevent methylprednisolone-induced inhibition of wound healing
(Osaka, 1997). In vitro experiments have also revealed that TGF-son, 1997). TGF-β1 is a very potent stimulant for collagen
deposition and inhibits collagen breakdown by the induction of a β1 can partly counteract the action of glucocorticoids, providing
molecular interpretations for the suppression of wound healingtissue inhibitor of metalloproteinase (Laiho et al, 1987). TGF-β1
increases the rate of formation of granulation tissue in vivo and (Fassler et al, 1996) and thus, TGF-β1 has critical regulatory roles
in tissue repair and remodeling. Increased transcription of TGF-β1stimulates epidermal migration and epidermis regrowth (Mustoe
et al, 1987; Pierce et al, 1989). Particle-mediated gene transfer with in cells of the wound bed may be responsible for the higher levels
of TGF-β1 in the wound tissue. The endogenous production ofTGF-β1 cDNA enhances wound repair in rat skin (Benn et al,
1996). A reduced endogenous production of TGF-β1 was found TGF-β1 by arnebin-1 could lead to the increased granulation
tissue deposition and faster re-epithelialization, and may partly bein wounds of adramycin-treated animals and the supplementation
of the exogenous TGF-β1 accelerates the impaired healing wounds responsible for improved healing in hydrocortisone-treated animals.
Arnebin-1 has been demonstrated to be active also against Walker(Lawrence et al, 1986).
Glucocorticoids suppressed TGF-β1, TGF-β2, and TGF-β tIIrc carcinosarcoma in rats (Gupta and Mathur, 1972). Wound healing
properties, however, are not normally associated with anti-cancerin normal and wounded skin (Frank et al, 1996). Dexamethasone
abrogates the fibrogenic effect of TGF-β1 in rat granuloma and activity, as several anti-tumor agents such as adriamycin, actinomy-
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